Fan Zhou1,2, Dongjiao Wang3, Wei Wei3, Haimin Chen3, Haotian Shi3, Nian Zhou3, Lixia Wu3, Rong Peng3. 1. Department of Hematology and Oncology, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China. zfsh257@163.com. 2. Myeloma cooperative group of Shanghai district and county blood alliance, Shanghai, China. zfsh257@163.com. 3. Department of Hematology and Oncology, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China.
Abstract
BACKGROUND: This study aimed to explore the heterogeneity of circRNA expression pattern via microarray, and further evaluate the potential of 10 specific circRNAs as diagnostic and prognostic biomarkers in multiple myeloma (MM). METHODS: In exploration stage (stage I), circRNA expression profiles were detected by the microarray in bone marrow plasma cells from 4 MM patients and 4 healthy controls (HCs), and bioinformatic analyses were performed. In validation stage (stage II), top 10 upregulated and top 10 downregulated circRNAs identified in stage I were detected in 60 MM patients and 30 HCs for further validation; the diagnostic and prognostic values of these circRNAs in MM patients were analyzed. RESULTS: In stage I, 122 upregulated and 260 downregulated circRNAs were identified in MM patients compared with HCs. GO, KEGG and pathway enrichment analyses revealed that these circRNAs were implicated in neoplastic pathways such as MAPK and VEGF signaling pathways. In stage II, circ-PTK2, circ-RNF217, circ-RERE, circ-NAGPA and circ-KCNQ5 were validated to be upregulated and circ-AFF2, circ-WWC3, circ-DNAJC5, circ-KLHL2, circ-IQGAP1 and circ-AL137655 were validated to be downregulated in MM compared with controls. Circ-PTK2 and circ-RNF217 were correlated with poor treatment response and survival, while circ-AFF2 predicted good treatment response and survival in MM patients. CONCLUSIONS: This study provides valuable reference for profound understanding about circRNA expression patterns in MM, and validates that circ-PTK2, circ-RNF217 and circ-AFF2 might serve as potential prognostic biomarkers in MM.
BACKGROUND: This study aimed to explore the heterogeneity of circRNA expression pattern via microarray, and further evaluate the potential of 10 specific circRNAs as diagnostic and prognostic biomarkers in multiple myeloma (MM). METHODS: In exploration stage (stage I), circRNA expression profiles were detected by the microarray in bone marrow plasma cells from 4 MMpatients and 4 healthy controls (HCs), and bioinformatic analyses were performed. In validation stage (stage II), top 10 upregulated and top 10 downregulated circRNAs identified in stage I were detected in 60 MMpatients and 30 HCs for further validation; the diagnostic and prognostic values of these circRNAs in MMpatients were analyzed. RESULTS: In stage I, 122 upregulated and 260 downregulated circRNAs were identified in MMpatients compared with HCs. GO, KEGG and pathway enrichment analyses revealed that these circRNAs were implicated in neoplastic pathways such as MAPK and VEGF signaling pathways. In stage II, circ-PTK2, circ-RNF217, circ-RERE, circ-NAGPA and circ-KCNQ5 were validated to be upregulated and circ-AFF2, circ-WWC3, circ-DNAJC5, circ-KLHL2, circ-IQGAP1 and circ-AL137655 were validated to be downregulated in MM compared with controls. Circ-PTK2 and circ-RNF217 were correlated with poor treatment response and survival, while circ-AFF2 predicted good treatment response and survival in MMpatients. CONCLUSIONS: This study provides valuable reference for profound understanding about circRNA expression patterns in MM, and validates that circ-PTK2, circ-RNF217 and circ-AFF2 might serve as potential prognostic biomarkers in MM.
Authors: Lu Li; Jin Liu; Juan Du; Hua Jiang; Haiyan He; Jing Lu; Wanting Qiang; Nan Hou; Pei Guo; Yan Zhuang; Weijun Fu Journal: Oncol Rep Date: 2022-09-21 Impact factor: 4.136